Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain inhibitory neurons; strongest in myonuclei | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 108 | 0.91 |
| pathways Reactome | Reactome did not answer (Reactome: The operation was aborted due to timeout) | 0.00 |
No case: the score is under the bar. Receipt 4320
Sealed predictions
- SLC25A12 in dopamine neurons, braak+0.18 (p 0.646) → +0.77 (p 0.015)receipt 4328
Swarm cases
receipt 4328: SLC25A12 in dopamine neurons, braak
- power
- full sample +0.43 (p 0.072, n 18), 95% CI -0.04 to +0.75. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.48 (p 0.043, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.48 (p 0.043, n 18). not the mix.
- skeptic
- leave-one-out range +0.35 to +0.57, sign flips 0; without severely affected donors +0.43 (p 0.072, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SLC25A12 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts